Elasmogen Ltd2020-03-12T13:40:45+00:00
VTime Ltd

Elasmogen Ltd is a drug discovery and biopharmaceutical company spun out of the University of Aberdeen in 2016. The Company has developed a method of delivering drugs to specific sites in the human body using ‘biologic’ drugs (drugs derived from living organisms/components of living organisms). The ‘soloMER’ product is a fully-humanised protein domain derived from sharks that the Company have developed into a site-specific drug delivery mechanism. 

These fragments have been adapted for safe use in the human body – differentiating them from similar products based on human antibodies. They are small and stable and suitable for use as a site-specific drug delivery mechanism.  Specifically, they are 9% of the size of a human antibody, meaning they offer: 

• site-specific dosing;

• flexible formatting (bi or tri-functional products) to increase clinical efficacy; and

• reduction in manufacturing costs.

The initial intended applications are the treatment of auto-inflammatory diseases of the eye and oncology (cancer). The Company’s primary development target is topically-delivered soloMERs in the treatment of Uveitis (inflammation of the coloured section of the eye). The Company states that autoimmune-related inflammatory diseases of the eye are poorly served medical targets due to the difficulty of site-specific drug delivery. However, they believe that soloMER proteins make them capable of site-specific dosing. 

The Company is seeking to progress a number of internal and partnered programs and intends to take these targets to Phase 1 clinical trials to create significant stakeholder value before licensing them to pharmaceutical partners.

  • Sector: Drug discovery and Biopharma 

  • Region: UK: Scotland

  • Stage: Growth – pre-revenue

  • Eligible Tax: EIS

  • Funding: £2,000,218

  • Status: Live

33% Funded

Log in
  to join our private investor network.

Need to know more?

For further information please do not hesitate to get in touch.

Contact Us

This website uses cookies and third party services. Deepbridge Syndicate is designed for non-advised, appropriate investors looking to invest into single EIS-eligible companies, with a minimum investment of £10,000. For persons not meeting this criteria please visit www.deepbridgecapital.com.RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to sell shares; the loss of the value of investment; dilution of shareholding and investing in single company investment should be done only as part of a diversified portfolio. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme. Please read full Risk Warning. By continuing to view this website you are confirming you have read the above notification and risk warning.